Engineered Salmonella Therapy for Cancer Treatment
- A new immunotherapy, ACTM-838, developed by Actym Therapeutics, delivers immune-activating proteins directly to solid tumors, potentially overcoming resistance to existing cancer treatments.
- Solid tumors frequently enough create an immunosuppressive environment, hindering the effectiveness of immunotherapies like immune checkpoint inhibitors.
- Udyavar at Actym Therapeutics designed ACTM-838 to specifically address this challenge.
“`html
ACTM-838: Novel Bacterial immunotherapy Shows Promise Against Solid Tumors
Table of Contents
A new immunotherapy, ACTM-838, developed by Actym Therapeutics, delivers immune-activating proteins directly to solid tumors, potentially overcoming resistance to existing cancer treatments. Research published on October 6, 2025, in Oncotarget details the therapy’s mechanism and early promise.
The Challenge of Solid Tumor Immunotherapy
Solid tumors frequently enough create an immunosuppressive environment, hindering the effectiveness of immunotherapies like immune checkpoint inhibitors. These inhibitors, while triumphant in some cancers, frequently fail in solid tumors as the tumor microenvironment (TME) actively suppresses immune cell activity as explained by the National Cancer Institute. This suppression prevents immune cells from recognizing and attacking the cancer.
How ACTM-838 Works: A Targeted Approach
Researchers led by Kyle R. Cron and Akshata R. Udyavar at Actym Therapeutics designed ACTM-838 to specifically address this challenge. The therapy utilizes a bacterial delivery system to target phagocytic immune cells – cells that engulf and destroy foreign particles – within the TME. This targeted delivery ensures that immune-activating proteins are concentrated where thay are moast needed as detailed in News Medical Life Sciences.
Once inside the tumor, ACTM-838 releases two key components:
- IL-15/IL-15Rα: A cytokine that promotes the growth and activation of T cells and natural killer (NK) cells, crucial for anti-tumor immunity.
- modified STING: A signaling molecule that activates the innate immune system, triggering an inflammatory response and further enhancing anti-tumor immunity.
This dual-pronged approach aims to shift the TME from immunosuppressive to immunostimulatory, enabling a more robust and durable anti-tumor immune response.
Research Findings from Oncotarget
The study, published in Volume 16 of Oncotarget on October 6, 2025, demonstrated that ACTM-838 effectively enriched within solid tumors and successfully delivered its payloads of IL-15/IL-15Rα and modified STING. The researchers observed activation of both innate and adaptive immune responses within the TME, indicating that the therapy was achieving its intended effect as indexed by the National Center for Biotechnology Information.
While the research is currently preclinical, the results suggest that ACTM-838 could offer a significant advantage over existing immunotherapies by directly addressing the immunosuppressive nature of solid tumors.